BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

# Sosei Heptares and Pfizer collaborate for multi-target drug discovery

May 24, 2021 | News

**Announces that the third novel drug candidate has started clinical trials by Pfizer triggering US$5 million payment to Sosei Heptares**



Sosei Group Corporation has been notified by Pfizer that the first subject in a clinical trial has been dosed with a new drug candidate nominated from the multi-target drug discovery collaboration between the two companies. Achievement of this milestone triggers a payment of US$5 million to Sosei Heptares. This candidate was nominated for advancement by Pfizer in December 2019 generating a US$3 million milestone payment at that time.

Pfizer nominated three distinct clinical candidates from the collaboration with Sosei Heptares during 2019, all of which are now progressing in Phase I clinical trials. These candidates have also now been disclosed by Pfizer as:

- PF-07081532 (an oral GLP1 receptor agonist for Type 2 Diabetes Mellitus and Obesity)
- PF-07054894 (a CCR6 antagonist targeting Inflammatory Bowel Disease) and
- PF-07258669 (an MC4 receptor antagonist for Anorexia)

This candidate is the ninth GPCR-targeted drug candidate overall originating from Sosei Heptares' StaR® technology and structure-based drug design (SBDD) platform to enter clinical trials.

Dr. Rob Cooke, Chief Technology Officer of Sosei Heptares, said: "with the start of clinical trials with this new clinical candidate the productivity is further exemplified by the fact that nine candidates derived from our platform have entered clinical trials across multiple disease areas, with more than 20 active programs underway either with partners or in house. This broad portfolio of exciting new drug candidates has potential to address significant unmet need globally and generate significant future value for shareholders."

Sosei Heptares and Pfizer entered a multi-target drug discovery collaboration in November 2015 to research and develop potential new medicines directed at GPCR targets across multiple therapeutic areas. Many of these targets have clinical or biological validation as key points for therapeutic intervention potentially targeting a range of diseases but have proven difficult to address with conventional discovery approaches because of inherent technical challenges.